Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study

Mei, H; Liu, XF; Li, Y; Zhou, H; Feng, Y; Gao, GX; Cheng, P; Huang, RB; Yang, LH; Hu, JD; Hou, M; Yao, YZ; Liu, L; Wang, Y; Wu, DP; Zhang, LS; Zheng, CC; Shen, XL; Hu, Q; Liu, J; Jin, J; Luo, JM; Zeng, Y; Gao, SJ; Zhang, XH; Zhou, X; Shi, QZ; Xia, RX; Xie, XB; Jiang, ZX; Gao, L; Bai, YS; Xiong, JY; Li, RZ; Zou, JJ; Niu, T; Yang, RC; Hu, Y

Hu, Y (通讯作者),Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hematol, Wuhan 430000, Hubei, Peoples R China.;Niu, T (通讯作者),Sichuan Univ, West China Hosp, Inst Hematol, Dept Hematol, Chengdu 610041, Sichuan, Peoples R China.;Yang, RC (通讯作者),Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Natl Clin Res Ctr Hematol Disorders, Thrombosis & Hemostasis Ctr,State Key Lab Expt He, Tianjin 300020, Peoples R China.;Yang, RC (通讯作者),Chinese Acad Med Sci & Peking Union Med Coll, Blo

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022; 20 (3): 716

Abstract

Background The efficacy of hetrombopag in Chinese patients with immune thrombocytopenia (ITP) has been demonstrated in a randomized, double-blind, pla......

Full Text Link